BenzingaOctober 20, 2026 at 10:12 AM NY7 Days Ago
Oppenheimer Maintains Outperform on BridgeBio Oncology, Lowers Price Target to $16
Oppenheimer analyst Mazahir Alimohamed maintains BridgeBio Oncology (NASDAQ:BBOT) with a Outperform and lowers the price target from $22 to $16.
What This Story Means
Claude is explaining the story in plain words…
Read the Full Story at the Source
The summary here comes from the news provider; the rest of the article lives on the publisher's site: Benzinga
